219 related articles for article (PubMed ID: 26398429)
1. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.
Horiuchi Y; Takagi A; Uchida T; Akatsuka T
Oncol Rep; 2015 Dec; 34(6):2827-36. PubMed ID: 26398429
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
3. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
4. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
Gross DA; Graff-Dubois S; Opolon P; Cornet S; Alves P; Bennaceur-Griscelli A; Faure O; Guillaume P; Firat H; Chouaib S; Lemonnier FA; Davoust J; Miconnet I; Vonderheide RH; Kosmatopoulos K
J Clin Invest; 2004 Feb; 113(3):425-33. PubMed ID: 14755339
[TBL] [Abstract][Full Text] [Related]
5. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.
Hernandez J; Garcia-Pons F; Lone YC; Firat H; Schmidt JD; Langlade-Demoyen P; Zanetti M
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12275-80. PubMed ID: 12218171
[TBL] [Abstract][Full Text] [Related]
7. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
8. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
9. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
13. Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.
Li Y; Huang Y; Liang J; Xu Z; Shen Y; Zhang N; Liu Z; Zhao Y
Mol Biol Rep; 2013 Apr; 40(4):2781-7. PubMed ID: 23456642
[TBL] [Abstract][Full Text] [Related]
14. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
16. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
17. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
18. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
19. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
[TBL] [Abstract][Full Text] [Related]
20. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]